Kornimate/medical-research-clean huggingface dataset:
efficacy and safety study of pga (poly-gamma glutamic acid) for cervical intraepithelial neoplasia

Conditions: Cervical Intraepithelial Neoplasia

Summary: the purpose of this study is to determine the efficacy and the safety of pga(poly-gamma glutamic acid) for the the fertile women with cervical intraepithelial neoplasia (cin1).

this study is to compare the regression rate of cervical intraepithelial neoplasia (cin1) between the treatment group and the control group. the treatment group will be administered with pga (poly-gamma glutamic acid) for 4 weeks followed by 8 weeks observation. the control group will be observed for 12 weeks without any comparator.

Eligibility criteria:
inclusion criteria: * fertile women between age of 20 and 49 * patients with cervical intraepithelial neoplasia 1(cin1) * hpv(human papilloma virus) positive(+) * white blood cell count(wbc) over 4thous/ul, hemoglobin above over 9.0g/dl platelet over 150thous/ul and anc(absolute neutrophil count) over 1,500 10\^6/l * ast(aspartate aminotransferase) no less than 4 times higher than normal alt(alanine aminotransferase) no less than 4 times higher than normal * normal for ekg(electrocardiography) and no active disease detected trough chest x-ray * be informed of the nature of the study and will give written informed consent exclusion criteria: * malignant tumor in any organ other than cervical intraepithelial neoplasia * active liver disease, immune disorder and severe renal failure * leukemia, collagenosis, sclerosis, autoimmune disease, clinically significant allergic disease(mild allergic symptom not required medicine excluded) * diagnosed diabetes * taking any of followings affecting immunological reaction within 7 days (glucocorticoid, vitamins, health food and oriental medicine etc) * pregnancy and breastfeeding * registered in other clinical trials * patients whom the investigator considers inappropriate to participate in the study

Keywords: treatment of cervical intraepithelial neoplasia(cin1)
the availability and safety study of remimazolam besylate for injection on sedation of eras patients

Conditions: Analgesia; Postoperative Pain

Summary: this trial intends to evaluate remimazolam besylate's availability and safety compared with propofol.


Eligibility criteria:
inclusion criteria * meet criteria of enhanced recovery after surgery (eras); * mechanical ventilated when enrolled and have estimation of more than 10 hours of mechanical ventilation in icu * aged between 18-75 years old and 18kg/m2 ≤ bmi ≤ 30 kg/m2; * clearly know the purpose and objective of this clinical study and voluntarily enrolled. criteria of eras: (1) without dysfunction of nervous system or glasgow coma score \> 12; (2) a satisfied glucose level (random blood glucose\ 90mmhg with no usage of vasoactive agent during screening stage; (6) without mental illness (schizophrenia, depressive disorder), cognitive dysfunction (identified by mmse), epilepsy, history of abuse of psychotropic or anesthesia medication; (7) without disorder of coagulation function (pt/inr/aptt \> 1.5×upper limit), bleeding tendency (active peptic ulcer), under treatment of thrombolysis and anticoagulant; (8) without disorder of liver function (alt/ast \> 2×upper limit and total bilirubin\>1.5×upper limit); (9) without disorder of renal function (creatine or bun/urea\>1.5×upper limit); without dialysis patients. exclusion criteria * allergy to component of remimazolam besylate for injection; * woman in gestation and lactation period; * enrolled in other clinical trails in recent 3 months; * other circumstance that identified by researchers that do not suitable for this clinical trial.

Keywords: sedative remimazolam besylate postoperative sedation
do treatments for smoking cessation affect alcohol drinking?

Conditions: Alcohol Drinking

Summary: the purpose of this study is to examine the effect of smoking cessation medications on alcohol drinking. effect of 2mg/day, 1mg/day, placebo varenicline was evaluated. following 7 days of medication pre-treatment to achieve steady state levels, participants complete a laboratory session assessing alcohol self-administration behavior. study enrolls heavy drinking smokers (not tested under nicotine deprivation), non-daily smokers, and nonsmokers. volunteers are administered either varenicline (chantix) or placebo.


Eligibility criteria:
inclusion criteria: * 21 years old or older * able to read and write in english * smokers, non-daily smokers, and non-smokers * heavy drinkers and/or meet criteria for alcohol use disorders exclusion criteria: * any significant current medical or psychiatric conditions that would contraindicate the consumption of alcohol * significant hepatocellular injury * positive test result at intake appointments on urine drug screens conducted for opiates, cocaine, or benzodiazepines * women who are pregnant or nursing * suicidal, homicidal, or evidence of severe mental illness * prescription of any psychotropic drug in the 30 days prior to study enrollment * blood donation within the past 8 weeks * individuals who are seeking treatment for drinking or smoking or who have attempted to quit drinking or smoking within the past 3 months * specific exclusions for administration of bupropion not specified above including: having taken monoamine inhibitors in the past six weeks; history of anorexia or bulimia; previous hypersensitivity to bupropion; history of alcohol or drug dependence in the past year; history of seizure disorder of any etiology * known allergy to varenicline or taking h2blockers * participation within the past 8 weeks in other studies that involve additive blood sampling and/or interventional measures that would be considered excessive in combination with the current study * subjects likely to exhibit clinically significant alcohol withdrawal during the study

Keywords: alcohol smoking cessation varenicline bupropion smoking cessation medications
prolonged hospital stay after thoracoscopic anatomical lung resections

Conditions: Minimally Invasive Surgical Procedures; VATS; RATS Surgery; Pulmonary Lobectomy; Pulmonary Segmentectomy; Air Leakage; Postoperative Complication; Pain Postoperative

Summary: in this study, the reasons for prolonged hospital stay after thoracoscopic (video- or robot-assisted) anatomical lung resections are investigated. currently, whenever possible, these anatomical lung resections are performed thoracoscopically, as they offer significant improvements in terms of postoperative pain, number of postoperative complications, rehabilitation, tolerance for adjuvant chemotherapy, and length of hospital stay. the development of an 'enhanced recovery after surgery' (eras) protocol for lung surgery has further reduced hospital stay and the need for opioids for analgesia. despite the optimal implementation of the eras protocol, there are still patients who need to stay in the hospital longer than the median. the aim of this research is to investigate the reasons for this.


Eligibility criteria:
inclusion criteria: * patients referred for elective minimally invasive (uniportal or multiportal video- or robot-assisted) anatomical lung resection (lobectomy or segmentectomy) * informed consent obtained pre-operatively * age 18 years or older exclusion criteria: * patients younger than 18 years old * traumatic event as indication for lung resection * non-anatomical lung resections * thoracotomy * patients already hospitalized for other pathologies, pre-existent and not related to the lung surgery * urgent/emergency procedures
effects of resistant starch on bowel habits, fecal short chain fatty acids and gut microbiota in parkinson disease

Conditions: Parkinson Disease

Summary: the investigators will investigate the effects of an 8-week resistant starch (rs) supplementation (5 g twice a day) in patients with parkinson disease and matched controls on: 1. symptoms of constipation (assessed by clinical scores); 2. fecal short chain fatty acid concentrations (measured by chromatography); 3. gut microbiota composition.


Eligibility criteria:
main inclusion criteria: * written informed to participate * for patients: diagnosis of parkinson disease main exclusion criteria: * use of antibiotics, steroids or probiotic supplements * chronic or acute disorders of the gastrointestinal tract * history of gastrointestinal surgery (other than appendectomy) * for healthy controls: family history of neurodegenerative disorders
addressing nonsuicidal self-injury in schools

Conditions: Nonsuicidal Self-injury; Suicidal Ideation; Stigmatization; Help-Seeking Behavior; Perceived Social Support; Mental Well-being

Summary: the aim of this study is to study the effectiveness of a whole-school approach that addresses non-suicidal self-injury and targets adolescents, parents and teachers. whether training and interventions can influence nssi will be examined. furthermore, investigations will be conducted to examine whether this whole-school approach can reduce symptoms of mental health problems in adolescents, reduce stigma och increase help-seeking and perception of social support. using a clustered waitlist control design, six lower secondary schools were randomized to either intervention or waitlist during four months (control groups were then given the intervention). measures of nssi, suicidality, mental well-being, stigma, attitudes, help-seeking and perceived social support were administered at baseline, after the intervention and at 6, 12 and 18-months follow-up. two hundred and sixty-seven adolescents in seventh and eight grade participated in the study (135 active group and 132 control group). the interventions were delivered during four months. for adolescents, interventions were delivered in the class room and consisted of five sessions of the youth aware of mental health (yam) program and one additional session focusing specifically on knowledge, stigma and attitudes toward nssi (kras). parents were offered an online psychoeducation on nssi, as were all school staff during this time period. school health care personnel, nurses, psychologist and counsellors and other school staff, such as teachers' aids, support staff and mentors took part in a 2-day workshop on nssi and suicidality.


Eligibility criteria:
inclusion criteria: * being a student in grade 7 and 8 in lower secondary school exclusion criteria: * special classes for refugees recently arrived in sweden with insufficient knowledge of the swedish language * special classes for adolescents with intellectual disability

Keywords: prevention whole-school approach nonsuicidal self-injury suicidality stigma help-seeking mental health
pennsylvania consortium: clinical database

Conditions: Amyotrophic Lateral Sclerosis; Neurodegenerative Disease; Motor Neuron Disease

Summary: in order to streamline disease research in als and other motor neuron diseases, we have joined a consortium of clinical centers (hershey and university of pittsburgh) who will collaborate on clinical and basic research projects. as part of this collaboration, de-identified clinical data from subjects at each institution will be entered into a joint database kindly provided and maintained by the als hope foundation. this database is password protected and contains only de-identified information. in addition to clinical data, any research specimens that are available through irb approved tissue collections will be linked to the subject so that the collaborating investigators can share samples and have the maximum information. this will enhance the usefulness of each specimen. once established, the database will provide a resource in which clinical data on a large number of patients along with tissue (blood, urine, muscle, csf, and autopsy) samples will be readily available. this will expedite research by circumventing the delays in collecting specimens prospectively and increase the number of specimens available by allowing the collaborating researchers access to each others specimens. in each case there will be a formal request placed to use specimens that are at the other institutions. these specimens will be used for research in the als center of hope at the drexel university college of medicine and shared with outside investigators with valid irb approved protocols.


Eligibility criteria:
inclusion criteria: * clinical data on patients with motor neuron diseases (als, pls, bulbar palsy) and related disorders exclusion criteria: * any patient without a motor neuron disease or related disorder

Keywords: amyotrophic lateral sclerosis cerebrospinal fluid neurodegenerative disease motor neuron disease autonomic nervous system neurodegenerative diseases movement disorders
effectiveness of transcranial direct current stimulation for tkr

Conditions: Transcranial Direct Current Stimulation; Post Operative Pain

Summary: transcranial direct current stimulation (tdcs) is a technique of noninvasive cortical stimulation allowing significant modification of brain function used. clinical application of this technique could be helpful for pain, parkinson's disease, dystonia, cerebral palsy and dementia etc. and tdcs is safe with only mild, transient adverse effects. but there is few studies focused to postoperative states. the aim of this project is to reveal the effect of tdcs for postoperative pain after total knee replacement surgery,


Eligibility criteria:
inclusion criteria: * subjects who have scheduled elective spine surgery. exclusion criteria: * who has cognitive dysfunction before surgery. * who already has delirium before surgery. * who has pain disorder ( like crps) * who cannot reveal the one's pain.
docetaxel in treating patients with advanced cancer of the cervix

Conditions: Cervical Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of docetaxel in treating patients with advanced cancer of the cervix.

objectives: i. assess the antitumor activity of docetaxel as neoadjuvant chemotherapy in patients with locally advanced squamous cell carcinoma of the cervix. ii. assess the tumor response, toxic effect, and survival rate of this regimen in these patients. outline: patients receive docetaxel iv over 1 hour on day 1. treatment is repeated every 3 weeks for 3 courses. patients are followed every 3 months posttreatment. projected accrual: a total of 16-35 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven stage iib, iiia, iiib, and iva squamous cell carcinoma of the cervix bidimensionally measurable disease no bilateral hydronefrosis patient characteristics: age: any age performance status: who 0-2 life expectancy: at least 12 weeks hematopoietic: hemoglobin at least 10 g/dl leukocytes at least 4,000/mm3 platelet count at least 75,000/mm3 hepatic: bilirubin less than 1.25 times upper limit of normal (uln) ast less than 1.25 times uln renal: bun less than 30 mg/dl and creatinine less than 1.5 mg/dl or creatinine clearance at least 60 ml/min other: no prior or other concurrent malignancies, other than properly treated basal cell skin cancer prior concurrent therapy: not specified

Keywords: stage iii cervical cancer stage iib cervical cancer stage iva cervical cancer cervical squamous cell carcinoma
hypernet- hypertension screening

Conditions: Asymptomatic Hypertension

Summary: identify untreated, asymptomatic hypertension in er patients

this was a prospective study done with no intervention- the study has since been completed

Eligibility criteria:
inclusion criteria: * asymptomatic hypertension exclusion criteria: * cardiac symptoms
ascend go-2: study of rvt-1401 for the treatment of participants with active, moderate to severe graves' ophthalmopathy ( go )

Conditions: Graves' Ophthalmopathy (GO)

Summary: the purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of rvt-1401 in the treatment of active, moderate to severe go participants. in addition, the study is designed to characterize the effect of rvt-1401 exposure on reduction in anti-tshr igg


Eligibility criteria:
inclusion criteria: 1. male or female ≥18 years of age. 2. clinical diagnosis of graves' disease with hyperthyroidism associated with active, moderate to severe graves' ophthalmopathy (go) with a clinical activity score (cas) ≥4 for the most severely affected eye at screening and baseline (on the 7-item scale). 3. onset of active go within 9 months of screening. 4. moderate-to-severe active go (not sight-threatening but has an appreciable impact on daily life), usually associated with one or more of the following: lid retraction ≥2 millimeters (mm), moderate or severe soft tissue involvement, proptosis ≥3 mm above normal for race and gender, and/or inconstant or constant diplopia. 5. other, more specific inclusion criteria are defined in the protocol exclusion criteria: 1. use of any steroid (intravenous, oral, steroid eye drops) for the treatment of go or other conditions within 3 weeks prior to screening. steroids cannot be initiated during the trial. exceptions include topical and inhaled steroids which are allowed. 2. use of rituximab, tocilizumab, or any monoclonal antibody for immunomodulation within the past 9 months prior to baseline. 3. total igg level \<6 grams per liter (g/l) at screening. 4. absolute neutrophil count \<1500 cells per meter squared (cells/mm\^3) at screening. 5. participants with decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months at screening. 6. previous orbital irradiation or surgery for go. 7. other, more specific exclusion criteria are defined in the protocol

Keywords: imvt-1401 graves' orbitopathy thyroid eye disease
combined effect of cranial and cervical mobilization in patients with cgh

Conditions: Cervicogenic Headache

Summary: * the purposes of this study are: * to investigate the combined effect of cranial and cervical mobilization in patient with cervicogenic headache and there effect on : 1. perceptive neck pain intensity 2. perceptive headache intensity 3. pain by pressure 4. frequency of headache episodes 5. duration of headache episodes 6. medications uptakes


Eligibility criteria:
inclusion criteria: * pain originating at the neck and radiating to oculo-frontal-temporal regions. * symptom unilaterally. * symptom provocation through cervical movement and/or awkward cervical postural. * symptom provocation through external pressure application through palpation to associated posterior cervical spine segments with resultant symptom reproduction. * possible ipsilateral shoulder and/or arm pain of vague reference. * 15 or more headache episodes per month * no history of cervical operation or any disease that result in headache as colities -all patients will sign the informed consent before joining the study. exclusion criteria: * headache not of cervical origin * headache with autonomic involvement, dizziness, or visual disturbance * congenital conditions of the cervical spine * it is of primary concern to exclude serious or life-threatening pathology such as : * cranial tumors. * meningitis. * sub-arachnoid hemorrhage. * carotid artery,vertebral artery dissection. * history of cervical operation or any disease that result in headache as colitis * age less than 18 or more than 40 years * chronic maxillary sinusitis
integrated approaches to health and safety in a dynamic construction work environment

Conditions: Worker Health; Work Injury; Safety Climate; Pain

Summary: "all the right moves for subcontractors" aims to improve safety, health and well-being, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers (project, operations and safety) work together to collaboratively identify problems and strategies to improve their conditions of work. the intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and well-being detailed in harvard center for work, health and well-being's implementation guidelines (mclellan et al, 2016). the intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change. we will evaluate this program by measuring safety climate, health climate, pain and injury and health behaviors.


Eligibility criteria:
inclusion criteria: * all workers employed by the recruited contractors at the eligible worksites exclusion criteria: * companies with less than 5 workers
the relationship between fat free mass and toxicity of cytostatics in cancer patients

Conditions: Pancreas Cancer; Colorectal Cancer

Summary: an observational study of the relationship between fat free mass and toxicity of cytostatics in cancer patients, at the department of clinical oncology at zealand university hospital, roskilde, denmark. fat free mass will be measured by bio impedance spectroscopy and data on toxicity will be obtained from medical records and interviews/questionnaires with the patients.

with a prospective observational design, this study will examine whether there is a correlation between the total dose of cytostatics per measured fat-free mass (ffm) (mg cytostatic agent/kg ffm) and toxicity of cytostatics among cancer patients. the study will include patients with a primary diagnosis of any stage colorectal or pancreatic cancer. the hypothesis is, that a higher total dose of cytostatics per ffm will correlate to more frequent and/or more severe toxicity than a lower total dose. in extension to this, we hypothesize that a loss of ffm during treatment, and thereby an increased total dose of cytostatics per ffm, will lead to more frequent and severe toxicity. recruitment and data collection will take place at the department of clinical oncology at zealand university hospital, roskilde over about a five month period. each patient will be included for two-four cycles of cytostatic treatment. ffm will be measured by bio impedance spectroscopy as close to the first day of each cycle of cytostatic treatment as possible. information about toxicity will be obtained from patient records and through interviews with the patients. interviews will be conducted at day 5 (4-6) of each cycle and at the end of each cycle. the interviews include questionnaires about specific toxicities, using national cancer institute (nci) patient-reported outcomes version of the common terminology criteria for adverse events (pro-ctcae), and overall health and quality of life, and 24-hour recall of dietary intake and questions about physical activity level. in short, relevant outcomes are change in ffm, hematology, grade 3/4 hematological toxicity as defined by nci ctcae, dose-limiting toxicity, hospitalization, patient-reported adverse events, overall health and quality of life, and nutritional intake.

Eligibility criteria:
inclusion criteria: * authorized individuals * understands, speaks and reads danish * patients referred for or who receives cytostatic treatment, and have a primary diagnosis of colorectal- or pancreatic cancer (diagnoses classified by international classification of diseases-10 as c18-21 and c25) * have the possibility of contact by telephone exclusion criteria: * pregnancy * breastfeeding * dementia * contraindications for bis measuring (pacemaker)

Keywords: cancer chemotherapy toxicity lean body mass cytostatics fat free mass dose-limiting toxicity adverse events adult quality of life nutrition